You are here: Industry Insights > FUJIFILM Diosynth Biotechnologies

News List

Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production contractpharma
January 12, 2021
Fujifilm Diosynth Biotechnologies, and the Texas A&M University System Center for Innovation in Advanced Development & Manufacturing (CIADM), have begun production on two different COVID-19 vaccine candidates with support from the U.S. government to ...
Collaboration Creates Bio Hub in Northern UK contractpharma
December 17, 2020
CPI, Fujifilm Diosynth Biotechnologies and Teesside University have formed a collaboration to accelerate the bioscience sector in the UK’s Tees Valley Region.
Fujifilm Diosynth to Manufacture Lilly COVID-19 Antibody contractpharma
October 15, 2020
Commercial manufacturing of the antibody therapy is expected to commence in April 2021.
Fujifilm Diosynth Biotechnologies Breaks Ground on Innovation Center in Texas contractpharma
August 21, 2020
The building will triple the sites' advanced therapies process development capabilities.
UK Govt. Buys 60 Million Doses of Novavax’ COVID-19 Vax Candidate contractpharma
August 18, 2020
Fujifilm Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UK.
CPI Partners with Perceptive Engineering and FujiFilm Diosynth Biotechnologies contractpharma
August 14, 2020
CPI, an independent technology innovation center, is partnering with Perceptive Engineering and FujiFilm Diosynth Biotechnologies.
Fujifilm Diosynth Biotechnologies Teams with COVID-19 Therapeutics Accelerator contractpharma
May 04, 2020
To reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies.
FUJIFILM Diosynth Biotechnologies Appoints CEO contractpharma
March 10, 2020
Steve Bagshaw, chief executive officer of FUJIFILM Diosynth Biotechnologies (FDB), has decided to retire from his current position, effective April 1, 2020.